EUVIMEDEUVIMED entdecken
Crossref

Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy

Vandana Krishna, Srashti Gopal Goyal, Venkata Vamsi Krishna Venuganti

Medical Oncology · 2026

DOI: 10.1007/s12032-026-03349-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, 2026. Verfasst von Vandana Krishna und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, Telangana, 500078, India. Hauptthemen laut MEDLINE: Survivin, RNA, Messenger, Nanoparticles, Mouth Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral carcinoma is the sixth most prevalent cancer type with a poor 5-year survival rate. mRNA-lipid nanoparticle-based immunotherapy can overcome the challenges associated with conventional treatment options. Here, we investigated the immunogenicity and antitumor efficacy of survivin antigen encoded mRNA lipid nanoparticles (LNPs) in combination with anti-CTLA-4 immune checkpoint inhibitor. Survivin mRNA was synthesized by in vitro transcription technique after cloning the antigenic target sequence into an expression vector. The mRNA-LNPs were prepared with lipids, ALC-0315, DOPE, and cholesterol using a droplet-based microfluidic device. The average particle size, polydispersity index and encapsulation efficiency of mRNA-LNPs was found to be 305 ± 68 nm, 0.11, and 65 ± 3.9%, respectively. Survivin mRNA-LNPs incubated with mouse-derived bone marrow dendritic cells showed activation of tumor-associated antigen specific T-cells. The co-culture of splenocytes, and cheek cells derived from C57BL/6 mouse administered with survivin mRNA-LNPs and CTLA-4 inhibitor with MOC-1 oral carcinoma cells showed significant (P < 0.05) reduction in the cancer cell viability compared with control group. The oral cancer cytotoxicity is attributed to the upregulation of MHCI and MHCII, CD8 + and CD4 + T-lymphocytes and reduction in the T-regulatory cells. Taken together, this study provides preliminary evidence for further development of survivin mRNA-LNPs and CTLA-4 inhibitor combination for oral cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SurvivinRNA, MessengerNanoparticlesMouth NeoplasmsCTLA-4 AntigenImmunotherapyT-Lymphocytes, CytotoxicImmune Checkpoint InhibitorsAnimalsMiceMice, Inbred C57BLHumansLipidsDendritic CellsCell Line, TumorFemaleLiposomes

Stichwörter der Autor:innen

CTLA-4 inhibitorImmunotherapyLipid nanoparticlesOral cancerSurvivin mRNA

Substanzen

SurvivinRNA, MessengerCTLA-4 AntigenLipid NanoparticlesBirc5 protein, mouseLipidsImmune Checkpoint InhibitorsLiposomes

Autor:innen und Institutionen

  • Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, Telangana, 500078, India.
  • Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, Telangana, 500078, India. vamsi@hyderabad.bits-pilani.ac.in.

Förderung

  • Science and Engineering Research Board

Zitieren

APA

Krishna, V., Goyal, S. G., & Venuganti, V. V. K. (2026). Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy. Medical Oncology. https://doi.org/10.1007/s12032-026-03349-9

Vancouver

Krishna V, Goyal SG, Venuganti VVK. Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy. Medical Oncology. 2026. doi:10.1007/s12032-026-03349-9

BibTeX
@article{Krishna2026,
  author = {Krishna, Vandana and Goyal, Srashti Gopal and Venuganti, Venkata Vamsi Krishna},
  title = {Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy},
  journal = {Medical Oncology},
  year = {2026},
  doi = {10.1007/s12032-026-03349-9}
}
Kostenlos starten →